Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model
Open Access
- 21 April 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4) , e10266
- https://doi.org/10.1371/journal.pone.0010266
Abstract
Over 14 million people die each year from infectious diseases despite extensive vaccine use [1]. The needle and syringe—first invented in 1853—is still the primary delivery device, injecting liquid vaccine into muscle. Vaccines could be far more effective if they were precisely delivered into the narrow layer just beneath the skin surface that contains a much higher density of potent antigen-presenting cells (APCs) essential to generate a protective immune response. We hypothesized that successful vaccination could be achieved this way with far lower antigen doses than required by the needle and syringe. To meet this objective, using a probability-based theoretical analysis for targeting skin APCs, we designed the Nanopatch™, which contains an array of densely packed projections (21025/cm2) invisible to the human eye (110 µm in length, tapering to tips with a sharpness of th of the delivered antigen. Our results represent a marked improvement—an order of magnitude greater than reported by others—for injected doses administered by other delivery methods, without reliance on an added adjuvant, and with only a single vaccination. This study provides a proven mathematical/engineering delivery device template for extension into human studies—and we speculate that successful translation of these findings into humans could uniquely assist with problems of vaccine shortages and distribution—together with alleviating fear of the needle and the need for trained practitioners to administer vaccine, e.g., during an influenza pandemic.Keywords
This publication has 43 references indexed in Scilit:
- Emergence and pandemic potential of swine-origin H1N1 influenza virusNature, 2009
- Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challengeProceedings of the National Academy of Sciences, 2009
- Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine LicensureClinical and Vaccine Immunology, 2009
- Transdermal Influenza Immunization with Vaccine-Coated Microneedle ArraysPLOS ONE, 2009
- Migratory Dermal Dendritic Cells Act as Rapid Sensors of Protozoan ParasitesPLoS Pathogens, 2008
- In Vivo Induction of Immune Responses to Pathogens by Conventional Dendritic CellsImmunity, 2008
- Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patchInfluenza and Other Respiratory Viruses, 2008
- Gene expression using an ultrathin needle enabling accurate displacement and low invasivenessBiochemical and Biophysical Research Communications, 2005
- Whiffs of selectionNature Genetics, 2000
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972